

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the prospectus dated Wednesday, November 20, 2024 (the “**Prospectus**”) issued by Hangzhou Jiuyuan Gene Engineering Co., Ltd. (杭州九源基因工程股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, Huatai Financial Holdings (Hong Kong) Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period on and after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Wednesday, December 25, 2024, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the H Shares could fall.

Potential investors of the Offer Shares should note that the Sole Sponsor and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.



Hangzhou Jiuyuan Gene Engineering Co., Ltd.

杭州九源基因工程股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 45,398,800 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 4,540,000 H Shares (subject to reallocation)
Number of International Offer Shares	: 40,858,800 H Shares (subject to reallocation and the Over-allotment Option)
Maximum Offer Price	: HK\$12.56 per H Share (plus brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565%, payable in full in Hong Kong dollars on application and subject to refund)
Nominal value	: RMB1.00 per H Share
Stock code	: 2566

*Sole Sponsor, Overall Coordinator, Joint Global Coordinator,
Joint Bookrunner and Joint Lead Manager*



Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager



Joint Bookrunners and Joint Lead Managers



**IMPORTANT NOTICE TO INVESTORS
OF HONG KONG OFFER SHARES**

FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering.

The Prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “*HKEXnews > New Listings > New Listing Information*” section, and the website of the Company at www.china-gene.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online through the **White Form eIPO** service at www.eipo.com.hk; or
- (2) apply electronically through the **HKSCC EIPO** channel and cause HKSCC Nominees to apply on your behalf by instructing your **broker** or **custodian** who is a HKSCC Participant to give **electronic application instructions** via HKSCC’s FINI system to apply for the Hong Kong Offer Shares on your behalf.

If you are an *intermediary, broker or agent*, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses stated above.

See the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares.

Your application through the **White Form eIPO** service or the **HKSCC EIPO** channel must be made for a minimum of 200 Hong Kong Offer Shares and in multiples of that number of Hong Kong Offer Shares as set out in the table below.

If you are applying through the **White Form eIPO** service, you may refer to the table below for the amount payable for the number of Hong Kong Offer Shares you have selected. You must pay the respective amount payable on application in full upon application for Hong Kong Offer Shares.

If you are applying through the **HKSCC EIPO** channel, you are required to pre-fund your application based on the amount specified by your broker or custodian, as determined based on the applicable laws and regulations in Hong Kong.

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (Stock Code: 2566)
(HK\$12.56 per Hong Kong Offer Share)

**NUMBER OF HONG KONG OFFER SHARES
THAT MAY BE APPLIED FOR AND PAYMENTS**

No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>
200	2,537.33	4,000	50,746.68	60,000	761,200.06	450,000	5,709,000.42
400	5,074.67	5,000	63,433.34	70,000	888,066.73	500,000	6,343,333.80
600	7,612.00	6,000	76,120.00	80,000	1,014,933.41	600,000	7,612,000.55
800	10,149.34	7,000	88,806.67	90,000	1,141,800.09	700,000	8,880,667.32
1,000	12,686.67	8,000	101,493.34	100,000	1,268,666.75	800,000	10,149,334.08
1,200	15,224.00	9,000	114,180.01	150,000	1,903,000.15	900,000	11,418,000.85
1,400	17,761.33	10,000	126,866.68	200,000	2,537,333.52	1,000,000	12,686,667.60
1,600	20,298.67	20,000	253,733.35	250,000	3,171,666.90	1,500,000	19,030,001.40
1,800	22,836.00	30,000	380,600.03	300,000	3,806,000.28	2,000,000	25,373,335.20
2,000	25,373.34	40,000	507,466.70	350,000	4,440,333.65	2,270,000 ⁽¹⁾	28,798,735.45
3,000	38,060.01	50,000	634,333.38	400,000	5,074,667.05		

- (1) Maximum number of Hong Kong Offer Share you may apply for.
- (2) The amount payable is inclusive of brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) and the SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy are paid to the Stock Exchange (in the case of the SFC transaction levy, collected by the Stock Exchange on behalf of the SFC; and in the case of the AFRC transaction levy, collected by the Stock Exchange on behalf of the AFRC).

No application for any other number of Hong Kong Offer Shares will be considered and such an application is liable to be rejected.

THE LISTING APPLICATION

The Company has applied to the Stock Exchange for the granting of listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering and the H Shares to be converted from Unlisted Shares. Assuming that the Hong Kong Public Offering becomes unconditional before 8:00 a.m. on Thursday, November 28, 2024, dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. in Hong Kong on Thursday, November 28, 2024.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 4,540,000 Offer Shares (subject to reallocation) representing approximately 10.0% of the total number of Offer Shares available under the Global Offering, and
- the International Offering of initially 40,858,800 Offer Shares (subject to reallocation and Overall-allotment Option), representing approximately 90.0% of the total number of Offer Shares available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 to the Listing Rules and Chapter 4.14 (Offering-related Mechanisms) of the Guide, the Overall Coordinators may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Chapter 4.14 (Offering-related Mechanisms) of the Guide, if such reallocation is done other than pursuant to the clawback mechanism as described in the section headed “Structure of the Global Offering — the Hong Kong Public Offering — Reallocation” in the Prospectus, the total number of Offer Shares available under the Hong Kong Public Offering following such reallocation shall be 9,079,800 Offer Shares (representing approximately 20% of the Offer Shares initially available under the Global Offering) and the final price shall be fixed at the bottom end of the indicative price range (i.e., HK\$11.48).

PRICING

The Offer Price will not be more than HK\$12.56 per Offer Share and is currently expected to be not less than HK\$11.48 per Offer Share, unless otherwise announced. Applicants under the Hong Kong Public Offering must pay, on application, the maximum Offer Price of HK\$12.56 per Offer Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%, amounting to a total of HK\$2,537.33 for one board lot of 200 H Shares, subject to refund.

EXPECTED TIMETABLE⁽¹⁾

Hong Kong Public Offering commences 9:00 a.m. on
Wednesday, November 20, 2024

Latest time to complete electronic applications under
White Form eIPO service through the designated
website at www.eipo.com.hk 11:30 a.m. on
Monday, November 25, 2024

Application lists of the Hong Kong
Public Offering open 11:45 a.m. on
Monday, November 25, 2024

Latest time (a) to complete payment of
White Form eIPO applications by effecting
internet banking transfer(s) or PPS payment
transfer(s) and (b) give **electronic application
instructions** to HKSCC. 12:00 noon on
Monday, November 25, 2024

If you are instructing your **broker** or **custodian** who is a HKSCC Participant will submit an **electronic application instructions** on your behalf through HKSCC's FINI system in accordance with your instruction, you are advised to contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by **broker** or **custodian**.

Application lists of the Hong Kong
Public Offering close. 12:00 noon on
Monday, November 25, 2024

Expected Price Determination Date. Tuesday, November 26, 2024

Announcement of the Final Offer Price, the results of applications in the Hong Kong Public Offering, the level of indications of interest in the International Offering and the basis of allocation of the Hong Kong Offer Shares under the Hong Kong Public Offering to be published on the websites of the Stock Exchange at www.hkexnews.hk and the website of our Company at www.china-gene.com at or before 11:00 p.m. on Wednesday, November 27, 2024

Results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- A full announcement of the Hong Kong Public Offering to be published on the websites of the Stock Exchange at www.hkexnews.hk and the website of our Company at www.china-gene.com respectively. no later than 11:00 p.m. on Wednesday, November 27, 2024
- Results of allocations in the Hong Kong Public Offering will be available at www.iporesults.com.hk (alternatively: www.eipo.com.hk/eIPOAllotment) with a “search by ID” function on a 24-hour basis from 11:00 p.m. on Wednesday, November 27, 2024 to 12:00 midnight on Tuesday, December 3, 2024
- Allocation results telephone enquiry by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. from Thursday, November 28, 2024 to Tuesday, December 3, 2024 (excluding Saturday, Sunday and public holiday in Hong Kong)

Despatch of H Share certificates into CCASS in respect of wholly or partially successful application under the Hong Kong Public Offering on Wednesday, November 27, 2024

Despatch of H Share certificates in respect of wholly or partially successful applications pursuant to the Hong Kong Public Offering on or before Wednesday, November 27, 2024

Dispatch/collection of refund cheques and **White Form** e-Refund payment instructions in respect of (i) wholly or partially successful applications (if applicable) and (ii) wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering on or before Thursday, November 28, 2024

Dealings in the H Shares on the Stock Exchange expected to commence at 9:00 a.m. on Thursday, November 28, 2024

Note:

(1) All dates and times refer to Hong Kong local time and dates unless otherwise stated.

SETTLEMENT

Subject to the granting of the listing of, and permission to deal in, the H Shares on the Stock Exchange and the Company's compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or any other date as determined by HKSCC. Settlement of transactions between Exchange Participants (as defined in the Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and the HKSCC Operational Procedures in effect from time to time. Potential investors should seek the advice of their stockbroker or other professional advisor for details of the settlement arrangements as such arrangements may affect their rights and interests. All necessary arrangements have been made for enabling the H Shares to be admitted into CCASS.

ELECTRONIC APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9:00 a.m. on Wednesday, November 20, 2024 and end at 12:00 noon on Monday, November 25, 2024 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
White Form eIPO Service	www.eipo.com.hk	Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Wednesday, November 20, 2024 to 11:30 a.m. on Monday, November 25, 2024, Hong Kong time. The latest time for completing full payment of application monies will be 12:00 noon on Monday, November 25, 2024, Hong Kong time.
HKSCC EIPO channel	Your broker or custodian who is an HKSCC Participant will submit electronic application instructions on your behalf through HKSCC's FINI system in accordance with your instruction.	Investors who would not like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian .

The **White Form eIPO** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

For those applying through the **White Form eIPO** service, the application monies (including brokerage, SFC transaction levy, Stock Exchange trading fee and AFRC transaction levy) will be held by the receiving bank(s) on behalf of the Company and the refund monies, if any, will be returned to you without interest on Thursday, November 28, 2024.

For those applying through the **HKSCC EIPO** channel, your broker or custodian will arrange the refund monies, if any, to your designated bank account subject to the arrangement application monies paid between you and it.

Please refer to the sections headed "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, and on the designated website at www.eipo.com.hk for the White Form eIPO service.

PUBLICATION OF RESULTS

The Company expects to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on the Stock Exchange's website at www.hkexnews.hk and our website at www.china-gene.com by no later than 11:00 p.m. on Wednesday, November 27, 2024 (Hong Kong time).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed "How to Apply for Hong Kong Offer Shares — Publication of Results" in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering as set out in the section headed "Structure of the Global Offering — Conditions of the Global Offering" in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, Stock Exchange trading fee and AFRC transaction levy, will be refunded, without interest, as described in the section headed "How to Apply for Hong Kong Offer Shares — D. DESPATCH/COLLECTION OF SHARE CERTIFICATES AND REFUND OF APPLICATION MONIES" in the Prospectus.

No temporary document of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid evidence of title at 8:00 a.m. on Thursday, November 28, 2024 provided that (i) the Global Offering has become unconditional in all respects and (ii) the right of termination as described in "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus has not been exercised. Investors who trade H Shares on the basis of publicly available allocation details or prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Thursday, November 28, 2024, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Thursday, November 28, 2024. The H Shares will be traded in board lots of 200 H Shares each and the stock code of the H Shares will be 2566.

This announcement is available for viewing on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.china-gene.com.

By order of the Board
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
杭州九源基因工程股份有限公司

FU Hang

Executive Director, Chairman of the Board and General Manager

Hong Kong, November 20, 2024

As at the date of this announcement, the Board comprises Mr. FU Hang (傅航) and Mr. ZHOU Wei (周偉) as executive Directors; Ms. MA Honglan (馬紅蘭), Mr. WU Shihang (吳詩航), Mr. Albert ESTEVE Cruella and Mr. FEI Junjie (費俊傑) as non-executive Directors; and Dr. ZHOU Zhihui (周智慧), Dr. ZHOU Demin (周德敏), Ms. HO Mei Yi (何美儀) as independent non-executive Directors.